Union Square Park Capital Management LLC Purchases Shares of 10,000 Molina Healthcare, Inc $MOH

Union Square Park Capital Management LLC bought a new stake in Molina Healthcare, Inc (NYSE:MOH) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 10,000 shares of the company’s stock, valued at approximately $1,914,000.

Several other hedge funds have also recently bought and sold shares of the company. CYBER HORNET ETFs LLC acquired a new position in Molina Healthcare in the 2nd quarter valued at about $45,000. MUFG Securities EMEA plc acquired a new stake in shares of Molina Healthcare during the second quarter worth about $48,000. Bogart Wealth LLC acquired a new stake in shares of Molina Healthcare during the third quarter worth about $39,000. SJS Investment Consulting Inc. boosted its stake in shares of Molina Healthcare by 6,225.0% in the third quarter. SJS Investment Consulting Inc. now owns 253 shares of the company’s stock valued at $48,000 after purchasing an additional 249 shares during the period. Finally, Pilgrim Partners Asia Pte Ltd purchased a new position in shares of Molina Healthcare in the third quarter valued at approximately $50,000. Institutional investors and hedge funds own 98.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on MOH shares. Wells Fargo & Company set a $141.00 target price on shares of Molina Healthcare and gave the stock an “equal weight” rating in a report on Friday, February 20th. Truist Financial lowered their target price on Molina Healthcare from $190.00 to $145.00 and set a “hold” rating for the company in a research note on Tuesday, February 17th. Cantor Fitzgerald cut their price target on Molina Healthcare from $180.00 to $144.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. UBS Group set a $173.00 price target on Molina Healthcare in a research report on Friday. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Molina Healthcare in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Molina Healthcare presently has an average rating of “Hold” and a consensus price target of $169.21.

Molina Healthcare Price Performance

Shares of MOH opened at $149.08 on Friday. The firm has a market capitalization of $7.68 billion, a price-to-earnings ratio of 17.42 and a beta of 0.52. The firm’s fifty day simple moving average is $163.64 and its 200-day simple moving average is $167.17. Molina Healthcare, Inc has a twelve month low of $121.06 and a twelve month high of $359.97. The company has a current ratio of 1.69, a quick ratio of 1.69 and a debt-to-equity ratio of 0.97.

Molina Healthcare (NYSE:MOH) last issued its earnings results on Thursday, February 5th. The company reported ($2.75) EPS for the quarter, missing analysts’ consensus estimates of $0.43 by ($3.18). The firm had revenue of $11.38 billion for the quarter, compared to analyst estimates of $10.90 billion. Molina Healthcare had a return on equity of 13.60% and a net margin of 1.04%.The business’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.05 EPS. Molina Healthcare has set its FY 2026 guidance at 5.000- EPS. Equities analysts forecast that Molina Healthcare, Inc will post 24.4 EPS for the current fiscal year.

Molina Healthcare Profile

Molina Healthcare, Inc is a managed care company specializing in government-sponsored health insurance programs. The company offers Medicaid managed care plans, Medicare Advantage and prescription drug plans, and individual Marketplace plans under the Affordable Care Act. Through an integrated care model, Molina emphasizes preventive and primary care services, care coordination, and disease management to improve health outcomes for its members.

The company traces its roots to the early 1980s, when Dr.